T
2K7
vs
D
DAX Index
Over the past 12 months, 2K7 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +11% growth.
Stocks Performance
2K7 vs DAX Index
Performance Gap
2K7 vs DAX Index
Performance By Year
2K7 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TCR2 Therapeutics Inc
Glance View
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 137 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm is conducting Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510, GPC3 and IL-15, which focuses on solid tumors, and CD70, which focuses on renal cell carcinoma. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor.
